The current investigation employs a directed neuromodulation technique, specifically targeting the right amygdala, to ascertain its therapeutic efficacy in managing depressive episodes. The intervention's safety and efficacy will be evaluated using an assessment incorporating depressive symptomatology, cognitive abilities, and daily functions.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
92
An 8-channel TIS device developed by NEURODOME Corporation.
Ruijin Hospital
Shanghai, Shanghai Municipality, China
Shanghai East Hospital
Shanghai, China
Tianjin Anding Hospital (Mental Health Center of Tianjin Medical University)
Tianjin, China
Quick Inventory of Depressive Symptomatology - Self-Report (16-item version)
Time frame: 4 weeks
Hamilton Depression Rating Scale (17-item version)
Time frame: Baseline, 1 week, 4 weeks and 8 weeks
Quick Inventory of Depressive Symptomatology - Self-Report (16-item version)
Time frame: Baseline, 1 week and 8 weeks
Snaith-Hamilton Pleasure Scale
The SHAPS is a questionnaire that used to measure the severity of anhedonia, a common symptom in various mental health conditions.
Time frame: Baseline, 1 week, 4 weeks and 8 weeks
Hamilton Anxiety Rating Scale
Time frame: Baseline, 4 weeks and 8 weeks
Pittsburgh Sleep Quality Index
Time frame: Baseline, 4 weeks and 8 weeks
36-Item Short Form Health Survey
Time frame: Baseline and 8 weeks
World Health Organization Quality of Life Assessment - Brief Version
Time frame: Baseline and 8 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.